CRC 10097: Phase Ib with Expansion of Patients at the MTD Study of AUY922 and Cetuximab in Patients with KRAS Wild-Type Metastatic Colorectal Cancer
- Type of Study
- Cancer (Oncology) - Colorectal
- Swedish Cancer Institute
- Short Description
Purpose: The study will determine the maximum tolerated dose (MTD) of AUY922 given in combination with cetuximab in previously treated patients with KRAS wild-type metastatic colorectal cancer.
- Open to Enrollment
- Principal Investigator
- Philip Gold, M.D.
- Eligibility Notes
- Histologically or cytologically confirmed colorectal cancer
- KRAS wild type metastatic colorectal cancer
- Progression of disease on at least 2 prior therapy to have included 5FU, or oxaliplatin or bevacizumab or irinotecan
- Prior treatment with cetuximab is allowed (full dose tolerated), provided that the patient never required a dose reduction due to toxicities
- Must have at least one measurable lesion
- No prior treatment with any Hsp90 inhibitor compounds
No patients who received systemic anti-cancer treatment prior to the first dose of AUY922 within the following time frames:
- Radiotherapy, conventional chemotherapy: within 2 weeks
- Palliative radiotherapy: within 2 weeks
- Nitrosoureas, monoclonal antibodies, such as trastuzumab and mitomycin: within 6 weeks
- Any continuous-dosing (i.e. daily dosing, every-other-day dosing, Monday-Wednesday-Friday dosing, weekly etc.) of systemic anti-cancer treatment for which the recover period is not known, or investigational drugs (i.e. targeted agents) within a duration of ≤ 5 half lives of the agent and their active metabolites (if any)
- More Info Link
- Additional information about the study summary and eligibility criteria may be viewed on the U.S. National Institutes of Health (NIH) website.
- (206) 215-3086